$7.05 Million in Sales Expected for Aptevo Therapeutics Inc (NASDAQ:APVO) This Quarter

Wall Street analysts forecast that Aptevo Therapeutics Inc (NASDAQ:APVO) will report $7.05 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aptevo Therapeutics’ earnings, with the highest sales estimate coming in at $7.10 million and the lowest estimate coming in at $7.00 million. Aptevo Therapeutics reported sales of $5.82 million in the same quarter last year, which indicates a positive year-over-year growth rate of 21.1%. The business is expected to issue its next quarterly earnings results on Wednesday, November 13th.

On average, analysts expect that Aptevo Therapeutics will report full year sales of $28.69 million for the current fiscal year, with estimates ranging from $28.00 million to $29.38 million. For the next year, analysts forecast that the business will post sales of $35.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Friday, August 9th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $7.36 million during the quarter, compared to the consensus estimate of $6.95 million. Aptevo Therapeutics had a negative return on equity of 148.97% and a negative net margin of 195.98%.



A number of brokerages recently commented on APVO. Roth Capital reiterated a “buy” rating on shares of Aptevo Therapeutics in a report on Thursday, May 23rd. Zacks Investment Research lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, ValuEngine upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $7.81.

In other news, Director Fuad El-Hibri bought 30,000 shares of Aptevo Therapeutics stock in a transaction on Monday, July 22nd. The shares were purchased at an average price of $0.89 per share, for a total transaction of $26,700.00. Following the acquisition, the director now owns 959,521 shares of the company’s stock, valued at $853,973.69. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marvin L. White bought 50,000 shares of Aptevo Therapeutics stock in a transaction on Friday, June 14th. The shares were purchased at an average price of $0.88 per share, for a total transaction of $44,000.00. Following the acquisition, the chief executive officer now directly owns 293,603 shares in the company, valued at approximately $258,370.64. The disclosure for this purchase can be found here. Insiders have acquired a total of 416,380 shares of company stock worth $340,044 in the last quarter. Company insiders own 11.74% of the company’s stock.

Several hedge funds have recently bought and sold shares of the business. Stonepine Capital Management LLC raised its holdings in Aptevo Therapeutics by 0.7% in the 2nd quarter. Stonepine Capital Management LLC now owns 3,922,891 shares of the biotechnology company’s stock worth $3,478,000 after purchasing an additional 28,672 shares during the period. Point72 Asset Management L.P. increased its stake in Aptevo Therapeutics by 6.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,350,000 shares of the biotechnology company’s stock worth $2,083,000 after buying an additional 150,000 shares in the last quarter. Renaissance Technologies LLC increased its stake in Aptevo Therapeutics by 32.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,644,856 shares of the biotechnology company’s stock worth $1,458,000 after buying an additional 406,930 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Aptevo Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after buying an additional 16,482 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Aptevo Therapeutics by 312.8% in the 2nd quarter. Acadian Asset Management LLC now owns 632,507 shares of the biotechnology company’s stock worth $560,000 after buying an additional 479,278 shares in the last quarter. Hedge funds and other institutional investors own 36.37% of the company’s stock.

Shares of APVO stock traded up $0.02 on Friday, hitting $0.76. 251,200 shares of the company’s stock were exchanged, compared to its average volume of 577,583. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.63 and a quick ratio of 2.91. Aptevo Therapeutics has a 12 month low of $0.49 and a 12 month high of $5.80. The stock has a market cap of $33.83 million, a P/E ratio of -0.32 and a beta of 2.39. The company has a 50 day moving average of $0.87 and a 200 day moving average of $0.98.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Read More: What is the strike price in options trading?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.